Journal article

Identification of binding sites for C-terminal pro-gastrin-releasing peptide (GRP)-derived peptides in renal cell carcinoma: a potential target for future therapy

Joseph Ischia, Oneel Patel, Kapil Sethi, Marianne S Nordlund, Damien Bolton, Arthur Shulkes, Graham S Baldwin

BJU International | WILEY-BLACKWELL | Published : 2015


OBJECTIVE: To determine the expression and biology of the neuroendocrine growth factor gastrin-releasing peptide (GRP) and other proGRP-derived peptides in renal cancer. MATERIALS AND METHODS: Receptor binding studies, enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay, were used to quantitate the presence of proGRP-derived peptide receptors and their ligands in renal cancer cell lines and human renal cancers. Biological activity of proGRP peptides was confirmed with proliferation, migration, and extracellular-signal-regulated kinases 1 and 2 (ERK1/2) activation assays in vitro. In vivo, ACHN renal cancer xenografts were treated with proGRP-derived peptides to assess tumour size ..

View full abstract


Awarded by Austin Health Medical Research Foundation

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

We thank Mildred Yim and Mike Chang for skilled assistance with radioimmunoassay and ELISA, respectively. This work was supported by grants from the Austin Health Medical Research Foundation and by grants 454408 and 628390 (to G.B and A.S.), 454322 (to G.B.) and 350235 (to A.S.) from the National Health and Medical Research Council of Australia. JI was supported by research scholarships from the NHMRC and the Royal Australian College of Surgeons.